Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum

Javed Butler, Muhammad Shariq Usman, Kevin J Anstrom, Robert O Blaustein, Marc P Bonaca, Justin A Ezekowitz, Cecilia Freitas, Carolyn S P Lam, Eldrin F Lewis, JoAnn Lindenfeld, Ciaran J McMullan, Robert J Mentz, Christopher O'Connor, Giuseppe M C Rosano, Clara Inés Saldarriaga, Michele Senni, James Udelson, Adriaan A Voors, Faiez Zannad, Javed Butler, Muhammad Shariq Usman, Kevin J Anstrom, Robert O Blaustein, Marc P Bonaca, Justin A Ezekowitz, Cecilia Freitas, Carolyn S P Lam, Eldrin F Lewis, JoAnn Lindenfeld, Ciaran J McMullan, Robert J Mentz, Christopher O'Connor, Giuseppe M C Rosano, Clara Inés Saldarriaga, Michele Senni, James Udelson, Adriaan A Voors, Faiez Zannad

Abstract

Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of adverse outcomes, even when treated with optimal guideline-directed medical therapy and in a clinically stable state. Soluble guanylate cyclase (sGC) stimulators have the potential to lower this risk by modifying the nitric oxide-sGC-cyclic guanosine monophosphate cascade - a pathophysiological pathway that has been targeted with limited success in HFrEF previously. Vericiguat, an sGC stimulator, was shown to improve outcomes in patients with HFrEF in the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. However, this trial included patients with recently worsening disease. In this brief review, we discuss the rationale of evaluating sGC stimulators in lower-risk HFrEF patients. First, all key HFrEF medications have been evaluated in both higher- and lower-risk populations, and the treatment effect is not always consistent across the risk spectrum. Second, pre-clinical studies and post-hoc studies of the VICTORIA trial have suggested that sGC stimulators may have cardioprotective effects - these effects may be more apparent when the medication is initiated earlier in the disease process. Third, the effect of vericiguat on cardiovascular mortality remains uncertain and a trial with a longer follow-up in a lower-risk population may allow better assessment of its effect on cardiovascular mortality. Therefore, there is a pertinent need to investigate the effects of vericiguat in optimally treated, low-risk HFrEF patients (i.e. those without recently worsening heart failure).

Keywords: HFrEF; Soluble guanylate cyclase stimulators; Vericiguat.

© 2022 European Society of Cardiology.

References

    1. Greene SJ, Fonarow GC, Butler J. Risk profiles in heart failure. Circ Heart Fail. 2020;13:e007132.
    1. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:2365-83.
    1. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of optimal Implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 2020;5:948-51.
    1. Greene SJ, Butler J, Fonarow GC. Contextualizing risk among patients with heart failure. JAMA. 2021;326:2261-2.
    1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.
    1. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.
    1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337.
    1. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016;4:816-22.
    1. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883-93.
    1. Lim SL, Lam CSP, Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36:2050-60.
    1. Hassan W. The endothelium and endothelin: beyond vascular reactivity. Ann Saudi Med. 2006;26:343-5.
    1. Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li P-L, et al. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci. 2018;19:2605.
    1. Massion PB, Feron O, Dessy C, Balligand J-L. Nitric oxide and cardiac function. Circ Res. 2003;93:388-98.
    1. Breitenstein S, Roessig L, Sandner P, Lewis KS. Novel sGC stimulators and sGC activators for the treatment of heart failure. In: Bauersachs J, Butler J, Sandner P, editors. Heart Failure. Cham: Springer International Publishing; 2017. p. 225-47.
    1. Al-Mohammad A. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2019;6:878-83.
    1. Cuffe MS, Califf RM, Adams JKF, Benza R, Bourge R, Colucci WS, et al.; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-7.
    1. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-75.
    1. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-73.
    1. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP, et al.; SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314:2251-62.
    1. Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, et al.; VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6:706-12.
    1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
    1. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
    1. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-28.
    1. Van Spall HGC, Averbuch T, Damman K, Voors AA. Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative? Eur J Heart Fail. 2021;23:1437-44.
    1. Skali H, Pfeffer MA, Lubsen J, Solomon SD. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation. 2006;114:2298-303.
    1. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2020;384:129-39.
    1. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
    1. Eichhorn EJ, Bristow MR. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med. 2001;2:20-3.
    1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35.
    1. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
    1. Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, et al.; Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol. 2021;7:17-25.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa